RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MELLQVIST UH
Collezione AOU Città della Salute di Torino

Items : 6

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. in The Lancet. Oncology / Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7.

2021
AOU Città della Salute di Torino

Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; van de Donk N; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; João C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; et alii...

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1. in British journal of haematology / Br J Haematol. 2021 Jun;193(6):1105-1109. doi: 10.1111/bjh.17302. Epub 2021 Jan 6.

2021
AOU Città della Salute di Torino

Byrne C; Nordström E; Sonneveld P; Reeves B; Mellqvist UH; Plesner T; Voorhees PM; Bringhen S; Harmenberg J; Obermüller J; Richardson PG;

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. in The Lancet. Haematology / Lancet Haematol. 2020 May;7(5):e395-e407. doi: 10.1016/S2352-3026(20)30044-2. Epub 2020 Mar 23.

2020
AOU Città della Salute di Torino

Anderson K; Nordström E; Chauhan D; Byrne C; Zubair H; Paba-Prada C; Reeves B; Mellqvist UH; Plesner T; Voorhees P; Bringhen S; Richardson PG; Harmenberg J; Palumbo A; Sonneveld P;

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. in The Lancet. Haematology / Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.

2020
AOU Città della Salute di Torino

Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; et alii...

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. in Leukemia / Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2.

2018
AOU Città della Salute di Torino

Beksac M; Waage A; van de Donk NWCJ; Weisel K; Kaiser M; Jackson G; Goldschmidt H; Leleu X; Cook G; Mateos MV; Garderet L; Zweegman S; Terpos E; San-Miguel JF; Dimopoulos MA; Cavo M; Mohty M; Hajek R; Boccadoro M; Avet-Loiseau H; Moreau P; Gay F; Einsele H; Facon T; Delforge M; Ludwig H; Mellqvist UH; Engelhardt M; Caers J; et alii...

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. in Leukemia / Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353.

2017
AOU Città della Salute di Torino

Ludwig H; Delforge M; Facon T; Einsele H; Gay F; Moreau P; Avet-Loiseau H; Boccadoro M; Hajek R; Mohty M; Cavo M; Dimopoulos MA; San-Miguel JF; Terpos E; Zweegman S; Garderet L; Mateos MV; Cook G; Leleu X; Goldschmidt H; Jackson G; Kaiser M; Weisel K; van de Donk NWCJ; Waage A; Beksac M; Mellqvist UH; Engelhardt M; Caers J; et alii...